Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Waste print paper generated cellulose-chitosan composite film for cell attachment application.

International journal of biological macromolecules·2026
Same author

OMNI: Optimized Multiview Network Integration with Heterogeneous Graph Attention for Biomedical Interaction Prediction.

Journal of chemical information and modeling·2026
Same author

Hormonal crosstalk in endophyte-mediated biotic stress resilience: from colonization to defence for sustainable agriculture.

Plant physiology and biochemistry : PPB·2026
Same author

M-Tune: imbalanced data handling in machine learning by tuning the decision threshold.

Molecular diversity·2026
Same author

Coconut oil/lauric acid-based nanodrug formulation: a multifunctional platform for enhancing cancer therapy and mitigating toxicity.

Frontiers in cell and developmental biology·2026
Same author

Promoter methylation of APC, P16, and WT1 genes among high-risk HPV infected women of North-Eastern states of India.

Indian journal of medical microbiology·2026

Related Experiment Video

Updated: May 5, 2026

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

Published on: August 20, 2016

8.3K

Biomarker driven drug repurposing for Fuchs' endothelial corneal dystrophy (FECD): a computational study.

Sarangthem Dinamani Singh1,2, Gayatri Gogoi3,2, Selvaraman Nagamani1,2

  • 1Advanced Computation and Data Sciences Division, CSIR-North East Institute of Science and Technology (CSIR-NEIST), Jorhat, Assam 785006 India.

In Silico Pharmacology
|December 12, 2025
PubMed
Summary

Fuchs' Endothelial Corneal Dystrophy (FECD) research identifies novel biomarkers and therapeutic targets. This study found potential drug candidates for treating this vision-impairing eye condition.

Keywords:
DEGsDrug repurposingFECDGene enrichment analysis

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
12:36

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1

Published on: July 22, 2022

5.0K

Related Experiment Videos

Last Updated: May 5, 2026

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

Published on: August 20, 2016

8.3K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
12:36

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1

Published on: July 22, 2022

5.0K

Area of Science:

  • Ophthalmology
  • Genomics
  • Pharmacology

Background:

  • Fuchs' Endothelial Corneal Dystrophy (FECD) is a progressive eye condition affecting vision.
  • Current treatment for FECD is limited to corneal transplantation.
  • Understanding FECD's molecular mechanisms is crucial for developing new therapies.

Purpose of the Study:

  • To identify potential biomarkers for FECD.
  • To uncover pathways involved in FECD pathogenesis.
  • To discover novel therapeutic targets and drugs for FECD treatment.

Main Methods:

  • Utilized Gene Expression Omnibus (GEO) dataset GSE171830.
  • Employed GEO2R for differential gene expression analysis.
  • Conducted Gene Ontology (GO), KEGG pathway, and Protein-Protein Interaction (PPI) analyses.
  • Performed virtual screening of FDA-approved drugs against identified targets.

Main Results:

  • Identified 2654 differentially expressed genes (DEGs) in FECD.
  • Uncovered key biomarkers including HLA-DRA, CSF1R, TNFRSF11B, and COL4A1.
  • Highlighted CSF1R and TNFRSF11B as promising therapeutic targets.
  • Screened FDA-approved drugs, identifying top candidates for each target.

Conclusions:

  • This study provides insights into FECD molecular mechanisms.
  • Identified biomarkers and targets offer potential for FECD diagnosis and treatment.
  • Discovered drugs may significantly impact FECD treatment and prevention strategies.